POXIVER-CM
POXIVER-CM Tablets contain a combination of Mebeverine 135 mg and Chlordiazepoxide 5 mg in an oral tablet formulation. This combination brings together Mebeverine, an antispasmodic agent, and Chlordiazepoxide, a benzodiazepine compound. The product is included in SupriMeda’s pharmaceutical portfolio for professional healthcare and institutional procurement.
POXIVER-CM is a combination pharmaceutical formulation documented for gastrointestinal conditions, including irritable bowel syndrome (IBS), where abdominal cramping and anxiety may occur together. Its defined composition and tablet dosage form make it identifiable by its brand name, active ingredients and individual strengths within a professional medicine catalogue.
For hospitals, pharmacies, doctors and healthcare procurement teams, POXIVER-CM Tablets can be listed with clear product specifications to support catalogue management, product identification and procurement enquiries. The formulation combines two pharmacologically distinct ingredients in a single tablet, with each ingredient identified by its respective strength.
Everything You, Need to Know
POXIVER-CM is presented in a carton pack of 10 × 10 tablets, as shown on the product packaging.
POXIVER-CM is available as an oral tablet formulation.
POXIVER-CM contains Mebeverine 135 mg and Chlordiazepoxide 5 mg per tablet, according to the product information in the SupriMeda document.